$56.62 +0.36 (%) Clovis Oncology Inc - NASDAQ

Jan. 18, 2017 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Conatus Soars On Novartis Deal, Early FDA Nod For Clovis Drug

    TalkMarkets | Dec. 21, 2016 | 10:55AM EST
  2. Tesaro Ovarian Cancer Drug Gets Priority Review After FDA OKs Clovis Med

    Investors Business Daily | Dec. 20, 2016 | 11:28AM EST
  3. Biotechs Fade Again In Late Day Sell-Off

    TalkMarkets | Dec. 19, 2016 | 20:51PM EST
  4. Clovis Jumps After Securing FDA Approval For Ovarian Cancer Drug

    TalkMarkets | Dec. 19, 2016 | 17:18PM EST
  5. Supernus Pharmaceuticals Breaks Out On Up Day For Biotech Stocks

    Investors Business Daily | Dec. 19, 2016 | 13:48PM EST
  6. Stocks Higher As 3 Medicals Hit Buy Points; No 'Star Wars' Bump For Hasbro

    Investors Business Daily | Dec. 19, 2016 | 13:37PM EST
  7. Clovis Stock Rallies After AstraZeneca-Rivaling Ovarian Cancer Win

    Investors Business Daily | Dec. 19, 2016 | 13:28PM EST
  8. Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win

    Investors Business Daily | Dec. 7, 2016 | 15:20PM EST
  9. Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO

    TalkMarkets | Oct. 12, 2016 | 11:14AM EST
  10. Poor Stock Action & Trading

    TalkMarkets | Oct. 11, 2016 | 18:21PM EST
  11. 6 Best Performing Drug Stocks Of September 2016

    TalkMarkets | Oct. 3, 2016 | 12:05PM EST
  12. 5 Top Performing Stocks Of The Best ETF Of Q3

    TalkMarkets | Sep. 30, 2016 | 10:47AM EST
  13. Gilead Slips As Former Bull Turns Bearish On Hep C Business

    TalkMarkets | Sep. 27, 2016 | 14:10PM EST
  14. Benzinga's Top Initiations

    Benzinga | Dec. 17, 2015 | 10:02AM EST
  15. Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib

    Benzinga | Dec. 15, 2015 | 16:16PM EST
  16. Benzinga's M&A Chatter for Tuesday December 1, 2015

    Benzinga | Dec. 1, 2015 | 19:29PM EST
  17. Kyle Bass Builds Bull Case for Clovis Oncology

    GuruFocus | Nov. 27, 2015 | 09:14AM EST
  18. Clovis Oncology Continues Lower After Consolidation

    Benzinga | Nov. 23, 2015 | 13:06PM EST
  19. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD | Nov. 21, 2015 | 08:15AM EST
  20. Morning Market Losers

    Benzinga | Nov. 17, 2015 | 09:56AM EST
  21. Benzinga's Top Downgrades

    Benzinga | Nov. 17, 2015 | 09:26AM EST
  22. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 17, 2015 | 08:18AM EST
  23. Biotech Clovis Oncology

    IBD | Nov. 16, 2015 | 18:41PM EST
  24. Mid-Afternoon Market Update: Dow Surges More Than 200 Points; Dillard's Shares Dip On Earnings Miss

    Benzinga | Nov. 16, 2015 | 15:12PM EST
  25. Mid-Day Market Update: Starwood Drops Following Announcement of Acquisition Deal With Marriott; Sunoco Shares Gain

    Benzinga | Nov. 16, 2015 | 12:16PM EST
  26. Clovis Stumbles, AstraZeneca Leads Cancer Drug Race

    IBD | Nov. 16, 2015 | 11:03AM EST
  27. What The FDA Gave Clovis Oncology In June 2013, It Has Taken Away

    Benzinga | Nov. 16, 2015 | 10:45AM EST
  28. Mid-Morning Market Update: Markets Edge Higher; Marriott To Acquire Starwood Hotels For $12.2B

    Benzinga | Nov. 16, 2015 | 10:09AM EST
  29. Morning Market Losers

    Benzinga | Nov. 16, 2015 | 09:58AM EST
  30. Genomics Out Of 'Caveman Era,' But Still A Ways To Go

    IBD | Oct. 5, 2015 | 07:02AM EST
  31. Clovis Oncology Announces U.S. and E.U. Regulatory Milestones for Rociletinib in the Treatment of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer

    Benzinga | Sep. 29, 2015 | 15:01PM EST
  32. Clovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer September 6-9, 2015

    Benzinga | Sep. 4, 2015 | 05:03AM EST
  33. Clovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLC

    Benzinga | Aug. 3, 2015 | 05:03AM EST
  34. Benzinga's Top Upgrades

    Benzinga | Jul. 20, 2015 | 08:14AM EST
  35. Clovis Oncology Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock

    Benzinga | Jul. 10, 2015 | 05:01AM EST
  36. Clovis Oncology Initiates Rolling NDA Submission to the FDA for Rociletinib in the Treatment of Advanced EGFR-Mutant Non-small Cell Lung Cancer

    Benzinga | Jul. 1, 2015 | 15:06PM EST
  37. Morning Market Losers

    Benzinga | Jun. 1, 2015 | 09:25AM EST
  38. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus | Apr. 14, 2015 | 20:01PM EST
  39. Clovis Technology Gets Big Boost From Goldman Upgrade

    IBD | Apr. 13, 2015 | 15:06PM EST
  40. Benzinga's Volume Movers

    Benzinga | Apr. 13, 2015 | 09:25AM EST
  41. Morning Market Gainers

    Benzinga | Apr. 13, 2015 | 08:41AM EST
  42. Benzinga's Top Upgrades

    Benzinga | Apr. 13, 2015 | 08:08AM EST
  43. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 13, 2015 | 07:12AM EST
  44. Goldman Sachs Upgrades Clovis Oncology To Buy

    Benzinga | Apr. 13, 2015 | 06:45AM EST
  45. Earnings Scheduled For February 25, 2015

    Benzinga | Feb. 25, 2015 | 04:07AM EST
  46. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  47. Morning Market Losers

    Benzinga | Nov. 19, 2014 | 09:53AM EST
  48. Clovis Oncology Enters Into Oncology Clinical Trial Collaboration With GlaxoSmithKline

    Benzinga | Nov. 17, 2014 | 17:00PM EST
  49. UPDATE: Stifel Reiterates On Clovis Oncology Following 3Q14 LPS

    Benzinga | Nov. 7, 2014 | 08:33AM EST
  50. Morning Market Losers

    Benzinga | Sep. 3, 2014 | 08:50AM EST
Trading Center